• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Nautilus Biotechnology to Announce First Quarter 2025 Financial Results on April 29, 2025

    4/16/25 8:00:00 AM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $NAUT alert in real time by email

    SEATTLE, April 16, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus")), a company pioneering a single-molecule proteome analysis platform, today announced it will report financial results for the first quarter 2025 before market open on Tuesday, April 29, 2025.

    The company's management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at: www.nautilus.bio.

    About Nautilus Biotechnology, Inc.

    With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Carlos, California, Nautilus is a development stage life sciences company working to create a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus' mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio

    Media Contact

    [email protected]

    Investor Contact

    [email protected]



    Primary Logo

    Get the next $NAUT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NAUT

    DatePrice TargetRatingAnalyst
    12/5/2024$1.75Neutral → Sell
    Goldman
    6/27/2024$6.00Buy
    Guggenheim
    6/3/2024$3.00Hold
    Jefferies
    1/6/2022$8.00Equal-Weight
    Morgan Stanley
    11/2/2021Outperform
    Cowen & Co.
    8/4/2021$10.00Neutral
    Goldman Sachs
    7/13/2021$13.00Buy
    Jefferies
    More analyst ratings